Adalimumab biosimilar - Fresenius Kabi

Drug Profile

Adalimumab biosimilar - Fresenius Kabi

Alternative Names: MSB-11022

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono
  • Developer Fresenius Kabi
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Plaque psoriasis
  • Phase III Rheumatoid arthritis
  • Research Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 16 Feb 2018 Efficacy and safety data from a phase III trial in Plaque psoriasis presented at the 76th Annual Meeting of the American Academy of Dermatology (AAD-2018)
  • 18 Dec 2017 Preregistration for Plaque psoriasis (Treatment-experienced) in European Union (SC)
  • 15 Nov 2016 Phase-III clinical trials in Rheumatoid arthritis (Treatment-experienced) in Hungary (SC) (EudraCT2016-002852-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top